Clovis Oncology's surging stock price gave the company the value it needed to acquire EOS for $10m in cash and $190m in Clovis common shares, and to access the private Italian firm's cancer drug lucitanib, which Boulder, Colorado-based Clovis has been tracking for two years.
Clovis Oncology's surging stock price gave the company the value it needed to acquire EOS for $10m in cash and $190m in Clovis common shares, and to access the private Italian firm's cancer drug lucitanib, which Boulder, Colorado-based Clovis has been tracking for two years.
"We have been interested in lucitanib for some time and are pleased to have acquired EOS to add this program...
Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.
The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.
The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.
The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.
The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.
The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.
Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.
